Spanish diagnostics firm Destina Genomica received €2.2 million from the European Innovation Council (EIC) to accelerate clinical transition of its LiverAce Combo assay for drug‑induced liver injury (DILI). The award supports movement toward CE‑IVD certification and broader clinical adoption. LiverAce Combo uses dynamic chemical labelling (DCL) for PCR‑free detection of nucleic acids and combines simultaneous measurement of RNA (miR‑122) and protein (total CK‑18) biomarkers on standard immunoassay platforms. The assay targets an unmet need in preclinical and clinical safety to identify early hepatotoxicity signals during drug development and in clinical monitoring.